SPARC Secures Favourable CESTAT Ruling for Rs 27.51 Crore CENVAT Credit Refund
Sun Pharma Advanced Research Company Ltd 路 Others (Uncategorized) 路 04 Oct 2026, 6:08 pm
SPARC Secures Favourable CESTAT Ruling for Rs 27.51 Crore CENVAT Credit Refund Sun Pharma Advanced Research Company Limited (SPARC) received a favourable ruling from the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai. The Tribunal dismissed the Revenue's appeal and upheld the Order-in-Appeal dated 27th Apr'18. Consequently, the Tribunal confirmed the company's entitlement to a refund of accumulated CENVAT credit amounting to Rs 2,751 Lakhs (Rs 27.51 crore), along with applicable consequential interest, effectively concluding the ongoing tax dispute in favour of SPARC.
Original exchange filing (PDF)
More announcements from Sun Pharma Advanced Research Company Ltd
- Receipt of No- Objection Letters from the Stock Exchanges for Reclassification of Promoter Group 路 12 Nov 2026
- Response of Clarification sought from BSE Limited 路 11 Nov 2026
- The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. 路 11 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 路 03 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026. 路 03 Nov 2026
- Sun Pharma Advanced Research Company Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 02 Nov 2026
- To consider and approve the financial results for the quarter and half year ended September 30, 2026 路 02 Nov 2026
